Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 607 of 5804
-
Radioactive therapy targets Hard-to-Treat cancers in new trial
Disease control OngoingPhase 2 study, single arm trial enrolling patients with a Gallium-68/Fluorine-18 prostate-specific membrane antigen (PSMA) positive positron emission tomography/Computed Tomography (PET/CT) in order to be treated with Lutetium-177 (177Lu) PSMA. Patients without risk factors for …
Phase: PHASE2 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Two-Drug combo shows promise in keeping head and neck cancer at bay
Disease control OngoingOpen-label, two-arm, prospective multicenter phase II clinical trial to determine the efficacy and safety of combined pembrolizumab and lenvatinib compared to pembrolizumab alone as maintenance therapy after definitive radiochemotherapy of locally advanced head and neck squamous …
Phase: PHASE2 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New antibody aims to dissolve lung clots with less bleeding risk
Disease control OngoingPhase II trial of TS23
Phase: PHASE2 • Sponsor: Translational Sciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy targets tough breast cancers in early trial
Disease control OngoingThe multicenter, two-cohort, non-comparative, open-label, phase II clinical trial SABINA aims to analyze the safety and efficacy of MEN1611 in monotherapy and in combination with eribulin, a non-taxane chemotherapy agent, in Hormone Receptor (HR)-known/Human Epidermial Growth Fac…
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Old antibiotic, new hope: doxycycline may shield TB patients from lasting lung harm
Disease control Recruiting nowTuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill health, such as pulmonary impairment after tuberculosis (PIAT) and cardiovascular disease (CVD). A recent Phase 2b double-blind randomised-controlled clinical …
Phase: PHASE3 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New Two-Step attack on aggressive lymphoma shows promise in early trial
Disease control Recruiting nowThis phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastuximab tesirine is a monoclonal …
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could less epinephrine save more lives in cardiac arrest?
Disease control Recruiting nowThe objective of this randomized controlled trial is to evaluate the effectiveness of a low cumulative dose of epinephrine compared to a standard cumulative dose of epinephrine during resuscitation from ventricular fibrillation (VF) or ventricular tachycardia (VT) in adult out-of…
Phase: PHASE4 • Sponsor: Unity Health Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug DNL343 tested in major ALS trial – hope for slowing disease?
Disease control CompletedThe HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen G will evaluate the safety and efficacy of a single study drug, DNL343, in participants with A…
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New study tests Team-Based approach to curb overdose risk
Disease control OngoingThis 3-year Hybrid Type 1 study will randomize 208 people with co-occurring substance use and mental health disorders (COD) referred from the Worcester Hub. This study seeks to evaluate the effectiveness of MISSION, a multi-component team approach, versus linkage with a Peer Spec…
Phase: NA • Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail shows promise for EGFR lung cancer
Disease control OngoingThis is a phase II, single-arm, multicenter trial, conducted through Latin American Coorperative Oncology Group (LACOG). Treatment-naïve patients with recurrent/metastatic NSCLCs harboring EGFR exon 19 deletions or exon 21 L858R point mutations will be enrolled. At baseline, an a…
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New attack plan for rare leukemia: CAR-T cells + stem cell transplant
Disease control OngoingThis is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) combined with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia.
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New antibiotic cocktails take on tough UTIs and kidney infections
Disease control CompletedPhase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).
Phase: PHASE3 • Sponsor: Meiji Seika Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug duo aims to tackle stubborn breast cancer before surgery
Disease control OngoingTo learn if sacituzumab govitecan and pembrolizumab, when given before surgery, can help to control early-stage triple negative breast cancer that has not responded well to other treatments.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Engineered immune cells take on childhood cancers in first human trial
Disease control Recruiting nowThis is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingIntroduction: Patients with autoimmune rheumatic diseases (ARDs), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PAs), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSS) , systemic sclerosis (SSc…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy targets hard-to-treat liposarcoma
Disease control OngoingParticipants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced). In addition, their DDLS either has come back after treatment (recurrent), has spread to different parts of your body (metastatic), or is unable to be…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for young cancer patients: experimental drug targets hard-to-treat ewing sarcoma
Disease control Recruiting nowThis study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This …
Phase: PHASE1, PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Mind over paralysis: Brain-Controlled implant aims to move arms again
Disease control Recruiting nowCervical spinal cord stimulation can elicit arm and hand movements through recruitment of proprioceptive neurons in the dorsal roots. In participants with cervical spinal cord injury, the spare roots bellow the lesion can be used to reactivate motor function. Decoding of motor in…
Phase: NA • Sponsor: Ecole Polytechnique Fédérale de Lausanne • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New immunotherapy combo aims to stop relapse in young blood cancer patients
Disease control Recruiting nowA Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high ri…
Phase: PHASE1 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New heart valve device tested in humans for first time
Disease control Recruiting nowThe main objective of this study is to evaluate the feasibility and safety of the GEMINUS system in patients with severe symptomatic aortic stenosis. This is a prospective, open label, multicentre, single arm, first in human clinical study. Clinical follow up for all patients w…
Phase: NA • Sponsor: Valve Medical • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC